BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34387382)

  • 1. EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency.
    Satou A; Nakamura S
    Cancer Med; 2021 Oct; 10(19):6777-6785. PubMed ID: 34387382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142.
    Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Shimada S; Eladl AE; Elsayed AA; Daroontum T; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
    Pathol Int; 2020 Aug; 70(8):481-492. PubMed ID: 32367595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
    Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
    J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
    Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
    Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma arising in patient with a history of EBV-positive mucocutaneous ulcer and EBV-positive nodal polymorphous B-lymphoproliferative disorder.
    Daroontum T; Kohno K; Inaguma Y; Okamoto A; Okamoto M; Kimura Y; Nagahama M; Sakakibara A; Satou A; Nakamura S
    Pathol Int; 2019 Jan; 69(1):37-41. PubMed ID: 30450620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.
    Gion Y; Doi M; Nishimura Y; Ikeda T; Filiz Nishimura M; Sakamoto M; Egusa Y; Nishikori A; Fujita A; Iwaki N; Nakamura N; Yoshino T; Sato Y
    Cancer Med; 2022 Jan; 11(2):417-432. PubMed ID: 34842351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review.
    Marques-Piubelli ML; Salas YI; Pachas C; Becker-Hecker R; Vega F; Miranda RN
    Pathology; 2020 Jan; 52(1):40-52. PubMed ID: 31706670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death-ligand 1 (PD-L1)
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
    Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
    PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type.
    Kohno K; Suzuki Y; Elsayed AA; Sakakibara A; Takahara T; Satou A; Kato S; Nakamura S; Asano N
    Am J Clin Pathol; 2020 Apr; 153(5):571-582. PubMed ID: 31977037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nodal EBV-positive polymorphic B cell lymphoproliferative disorder with plasma cell differentiation: clinicopathological analysis of five cases.
    Satou A; Tabata T; Suzuki Y; Sato Y; Tahara I; Mochizuki K; Oishi N; Takahara T; Yoshino T; Tsuzuki T; Nakamura S
    Virchows Arch; 2021 May; 478(5):969-976. PubMed ID: 33169195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Notch1 protein expression in methotrexate-associated lymphoproliferative disorders.
    Okatani T; Nishimura MF; Egusa Y; Yoshida S; Nishimura Y; Nishikori A; Yoshino T; Yamamoto H; Sato Y
    J Clin Exp Hematop; 2024 Mar; 64(1):1-9. PubMed ID: 38281745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate-associated lymphoproliferative disorder demonstrating composite lymphoma of EBV-negative diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer.
    Moriya K; Kikuti YY; Carreras J; Kondo Y; Shiraiwa S; Nakamura N
    J Clin Exp Hematop; 2020; 60(1):11-16. PubMed ID: 32224560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr Virus Positive B-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract.
    Ishikawa E; Satou A; Nakamura M; Nakamura S; Fujishiro M
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 2.
    de Jong D; Roemer MG; Chan JK; Goodlad J; Gratzinger D; Chadburn A; Jaffe ES; Said J; Natkunam Y
    Am J Clin Pathol; 2017 Feb; 147(2):153-170. PubMed ID: 28395108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HHV8-positive, EBV-positive Hodgkin lymphoma-like large B cell lymphoma: expanding the spectrum of HHV8 and EBV-associated lymphoproliferative disorders.
    Sanchez S; Veloza L; Wang L; López M; López-Guillermo A; Marginet M; Martínez A; Balagué O; Campo E
    Int J Hematol; 2020 Nov; 112(5):734-740. PubMed ID: 32529584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A look into the evolution of Epstein-Barr virus-induced lymphoproliferative disorders: a case study.
    Ambrosio MR; Rocca BJ; Ginori A; Mourmouras V; Amato T; Vindigni C; Lazzi S; Leoncini L
    Am J Clin Pathol; 2015 Nov; 144(5):817-22. PubMed ID: 26486748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.